Tevogen Bio (NASDAQ: TVGN) adds governance, pay and related-party details
Tevogen Bio (TVGN) filed an amended annual report (10-K/A) for 2025 to include Part III information, which typically covers governance, executive compensation, and related-party transactions, without updating financial results. The amendment details the company's board structure, executive pay—including CEO Ryan Saadi's $10.4 million total compensation in 2025—and significant related-party financial arrangements with The Patel Family, LLP and its affiliates. It also specifies that CEO Ryan Saadi beneficially owns 59.45% of outstanding common stock, with all directors and executives collectively holding 67.91%.
FEB 26·TipRanks→
Tevogen Bio Shareholders Approve Reverse Split Authorization
Tevogen Bio Holdings shareholders approved an amendment to the company's 2024 equity incentive plan and authorized a flexible reverse stock split at a ratio between 1-for-25 and 1-for-85, to be implemented at the board's discretion. Both proposals received strong support, aimed at adjusting the capital structure and equity incentives. TipRanks' AI Analyst, Spark, rates TVGN as Neutral due to very weak financial performance and a strong downtrend in technicals.
JAN 31·TradingView→
Tevogen Bio Holdings Inc Evaluates Special Cash Dividend
Tevogen Bio Holdings Inc. announced on January 30, 2026, that its Board of Directors is evaluating a special cash dividend for shareholders. This dividend is contingent upon the company achieving future financial milestones, including specific revenue and earnings targets, and is subject to final Board approval based on financial performance and capital needs. The company has provided no assurance regarding the timing or amount of any potential dividend.
